Related Experiment Videos
Nicotine for schizophrenia
1Newsam Centre, Seacroft Hospital, York Road, Leeds, West Yorkshire, UK, LS14 6WB. sumpear@yahoo.co.uk
The Cochrane Database of Systematic Reviews
|January 27, 2006
Summary
Research on nicotine for schizophrenia found no trials meeting inclusion criteria. Further randomized controlled trials are needed to investigate nicotine
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Trials
Background:
- High smoking rates in schizophrenia patients compared to the general population.
- Nicotine's potential role in alleviating psychotic symptoms.
Purpose of the Study:
- To examine the effects of nicotine and related products in schizophrenia treatment.
- Assess nicotine's efficacy as a sole or adjunctive therapy.
Main Methods:
- Searched Cochrane Schizophrenia Group's Register and other sources.
- Included randomized clinical trials comparing nicotine or related products.
- Independently inspected, quality assessed, and data extracted from studies.
Main Results:
- No trials met the inclusion criteria for the review.
- Lack of sufficient randomized controlled trials on nicotine for schizophrenia.
Conclusions:
- Further research using parallel group design randomized controlled trials is recommended.
- Investigate nicotine's effects on schizophrenia symptoms and antipsychotic side effects.
- Emphasize adherence to CONSORT guidelines for reporting research.